Cytek Biosciences, Inc. (CTKB)

Market Cap	512.39M
Revenue (ttm)	200.45M
Net Income (ttm)	-6.02M
Shares Out	128.10M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	37.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	629,131
Open	4.100
Previous Close	4.100
Day's Range	3.970 - 4.115
52-Week Range	3.980 - 7.630
Beta	1.42
Analysts	Buy
Price Target	7.00 (+75.0%)
Earnings Date	May 7, 2025

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent c...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 648
• Stock Exchange: NASDAQ
• Ticker Symbol: CTKB
• Website: https://cytekbio.com

Financial Performance

In 2024, Cytek Biosciences's revenue was $200.45 million, an increase of 3.85% compared to the previous year's $193.02 million. Losses were -$6.02 million, -50.44% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is $7.0, which is an increase of 75.00% from the latest price.

Price Target

$7.0

(75.00% upside)

Analyst Consensus: Buy